Clinical Trial Update: GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating subcutaneous GV1001 for mild to moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GV1001

Snippet

Sponsor: GemVax & Kael | Conditions: Mild to Moderate Alzheimer's Disease | Phase 2 | Status: COMPLETED